EA201100032A1 - Соединения пиридина - Google Patents

Соединения пиридина

Info

Publication number
EA201100032A1
EA201100032A1 EA201100032A EA201100032A EA201100032A1 EA 201100032 A1 EA201100032 A1 EA 201100032A1 EA 201100032 A EA201100032 A EA 201100032A EA 201100032 A EA201100032 A EA 201100032A EA 201100032 A1 EA201100032 A1 EA 201100032A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyridine compounds
medicines
preparation
compounds
cancer
Prior art date
Application number
EA201100032A
Other languages
English (en)
Other versions
EA020807B1 (ru
Inventor
Бернар Кристоф Барлам
Кевин Майкл Фут
Патрик Пле
Клиффорд Дейвид Джонс
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201100032A1 publication Critical patent/EA201100032A1/ru
Publication of EA020807B1 publication Critical patent/EA020807B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям, которые ингибируют функцию киназы фокальной адгезии, способам их получения, фармацевтическим композициям, содержащим их в качестве активного ингредиента, к их применению в качестве лекарственных средств и к их применению для приготовления лекарственных средств для применения при лечении у теплокровных животных, таких как люди, заболеваний, таких как рак.
EA201100032A 2008-06-17 2009-06-15 Соединения пиридина EA020807B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7305508P 2008-06-17 2008-06-17
PCT/GB2009/050675 WO2009153589A1 (en) 2008-06-17 2009-06-15 Pyridine compounds

Publications (2)

Publication Number Publication Date
EA201100032A1 true EA201100032A1 (ru) 2012-01-30
EA020807B1 EA020807B1 (ru) 2015-01-30

Family

ID=40896110

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100032A EA020807B1 (ru) 2008-06-17 2009-06-15 Соединения пиридина

Country Status (18)

Country Link
US (1) US8569298B2 (ru)
EP (1) EP2303861B1 (ru)
JP (1) JP5551689B2 (ru)
KR (1) KR101695501B1 (ru)
CN (1) CN102124000B (ru)
AU (1) AU2009261764B2 (ru)
BR (1) BRPI0914927B8 (ru)
CA (1) CA2726508C (ru)
CR (1) CR11854A (ru)
DO (1) DOP2010000390A (ru)
EA (1) EA020807B1 (ru)
EC (1) ECSP10010695A (ru)
ES (1) ES2472323T3 (ru)
HK (1) HK1155170A1 (ru)
IL (1) IL209727A0 (ru)
MX (1) MX2010014057A (ru)
WO (1) WO2009153589A1 (ru)
ZA (1) ZA201100388B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140155410A1 (en) * 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
WO2010068947A2 (en) * 2008-12-12 2010-06-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Nuclear export inhibitors of topoisomerase ii alpha
CA2774715C (en) 2009-07-27 2018-04-03 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
JP5607241B2 (ja) 2010-05-21 2014-10-15 ケミリア・エービー 新規ピリミジン誘導体
JP5936609B2 (ja) 2010-06-29 2016-06-22 ベラステム インコーポレイテッド キナーゼインヒビターの経口製剤
MX343894B (es) 2010-06-30 2016-11-28 Poniard Pharmaceuticals Inc * Síntesis y uso de inhibidores de cinasa.
CN103096977B (zh) 2010-07-02 2017-02-15 吉利德科学公司 作为离子通道调节剂的稠杂环化合物
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
EP2667871A4 (en) * 2011-01-26 2014-07-09 Glaxosmithkline Intellectual Property Ltd SUITS
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
JP5937111B2 (ja) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ Ｆａｋ阻害剤
AU2012230229A1 (en) 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
CA2834164A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (ru) 2011-07-01 2018-04-28
AU2013205306B2 (en) 2012-03-16 2015-09-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
MD4820C1 (ru) * 2014-06-17 2023-03-31 Pfizer Inc. Замещенные дигидроизохинолиноновые соединения
US9442005B2 (en) 2014-07-30 2016-09-13 Corning Optical Communications LLC Non-contact methods of measuring insertion loss in optical fiber connectors
AU2015369690B2 (en) 2014-12-23 2019-01-17 SMA Therapeutics Inc. 3,5-diaminopyrazole kinase inhibitors
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
JP2018519327A (ja) 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
EP3758491A1 (en) 2018-02-28 2021-01-06 Basf Se Use of pyrazole propargyl ethers as nitrification inhibitors
IL276745B2 (en) 2018-02-28 2023-10-01 Basf Se Use of N-functional alkoxy pyrazole compounds as nitrification inhibitors
JP2021517589A (ja) 2018-03-12 2021-07-26 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用
CN108912095B (zh) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 苯并咪唑类化合物及其制备方法和应用
EP4045485A1 (en) * 2019-10-18 2022-08-24 The Regents Of The University Of California 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders
AR125955A1 (es) 2021-05-21 2023-08-30 Basf Se Uso de un compuesto de alcoxi pirazol n-funcionalizado como inhibidor de nitrificación

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
DE10336184A1 (de) 2003-08-07 2005-02-24 Bayer Materialscience Ag Neue Katalysatoren für die selektive Isocyanatdimerisierung
JP4607879B2 (ja) * 2003-08-15 2011-01-05 ノバルティス アーゲー 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン
CA2571482A1 (en) 2004-06-21 2005-12-29 Pharmacia & Upjohn Company Llc Pyk2 inhibitors for stimulation of osteoblast function
GB0419160D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
AU2005322855B2 (en) 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
EP1966192B1 (en) * 2005-12-01 2012-10-17 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2634646C (en) 2005-12-21 2012-04-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
KR101149295B1 (ko) 2006-12-08 2012-07-05 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
DK2134689T3 (da) * 2007-03-16 2014-06-30 Scripps Research Inst Inhibitorer af fokal adhæsionskinase
BRPI0814423B1 (pt) * 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak

Also Published As

Publication number Publication date
IL209727A0 (en) 2011-02-28
JP5551689B2 (ja) 2014-07-16
BRPI0914927B8 (pt) 2021-05-25
AU2009261764B2 (en) 2013-01-10
BRPI0914927B1 (pt) 2020-10-06
MX2010014057A (es) 2011-03-21
DOP2010000390A (es) 2011-01-15
CA2726508A1 (en) 2009-12-23
ES2472323T3 (es) 2014-06-30
ZA201100388B (en) 2011-10-26
JP2011524411A (ja) 2011-09-01
EP2303861B1 (en) 2014-04-23
CN102124000B (zh) 2014-09-17
US20110166139A1 (en) 2011-07-07
EA020807B1 (ru) 2015-01-30
CR11854A (es) 2011-02-25
KR20110023884A (ko) 2011-03-08
WO2009153589A1 (en) 2009-12-23
HK1155170A1 (en) 2012-05-11
US8569298B2 (en) 2013-10-29
CN102124000A (zh) 2011-07-13
KR101695501B1 (ko) 2017-01-11
ECSP10010695A (es) 2011-01-31
BRPI0914927A2 (pt) 2017-06-20
AU2009261764A1 (en) 2009-12-23
CA2726508C (en) 2016-06-07
EP2303861A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
EA201100032A1 (ru) Соединения пиридина
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
EA202090662A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA202090258A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
EA201790267A1 (ru) Новые модуляторы киназ
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201400161A1 (ru) Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201291098A1 (ru) Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
BRPI0915084B8 (pt) composto, e, composição farmacêutica
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM